Last update June 1, 2020

Пибрентасвир

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Hepatitis C virus NS5A protein inhibitor.
Used in combination with glecaprevir in the treatment of chronic hepatitis C virus infection.
Oral administration in a daily dose for 8 to 16 weeks.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic characteristics (lelevated molecular weight and very high plasma protein binding: EMA 2019, AEMPS 2019, Smolders 2019) make it very unlikely its excretion into breast milk in significant amounts

Possible side effects are rare and mild.


See below the information of these related products:

  • Glecaprevir (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Maternal Hepatitis C Infection ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Alternatives

We do not have alternatives for Пибрентасвир.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Пибрентасвир belongs to this group or family:

Tradenames

Main tradenames from several countries containing Пибрентасвир in its composition:

  • Maviret™. Contains other elements than Пибрентасвир in its composition
  • Mavyret™. Contains other elements than Пибрентасвир in its composition

Pharmacokinetics

Variable Value Unit
Molecular weight 1.113 daltons
Protein Binding 100 %
Tmax 5 hours
13 - 29 hours

References

  1. EMA. Maviret (Glecaprevir + Pibrentasvir) Drug Summary 2019 Full text (in our servers)
  2. Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet. 2019 Oct;58(10):1237-1263. Abstract
  3. AEMPS. Maviret (Glecaprevir + Pibrentasvir) Ficha técnica. 2019 Full text (in our servers)

Total visits

504

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM